Vergleich

Tigecycline

ArtNr CS-1876-500mg
Hersteller ChemScene
Menge 500mg
Kategorie
Typ Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 220620-09-7
Lieferbar
Alternative Names
GAR-936
CAS
220620-09-7
Purity
>98%
Formula
C29H39N5O8
MWt
585.65
Solubility
DMSO : 150 mg/mL (256.13 mM; Need ultrasonic)
Clinical Information
Launched
Pathway
Anti-infection; Autophagy
Target
Bacterial; Autophagy
Biological Activity
Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL[1]. MIC50 and MIC90 are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii), respectively[2]. IC50 & Target: Mean MIC: 125 ng/mL (E. coli)[1]
MIC50: 1 mg/mL (A. baumannii)[2]
MIC90: 2 mg/mL (A. baumannii)[2]
In Vitro: Tigecycline (0.63-30 uM, preincubated for 4 days, treated for 72 h) inhibits AML2 cells and HL-60 cells with IC50s of 4.72+/-0.54 and 3.06+/-0.85 uM (freshly prepared). Tigecycline inhibits AML2 cells and HL-60 cells with IC50s of 5.64+/-0.55 and 4.27+/-0.45 uM (1 day preincubation). Tigecycline inhibits AML2 cells and HL-60 cells with IC50s of 5.02+/-0.60 and 4.39+/-0.44 uM (2 day preincubation). Tigecycline inhibits AML2 cells and HL-60 cells with IC50s of 4.09+/-0.41 and 3.95+/-0.39 uM (3 day preincubation). After a 4 day preincubation of Tigecycline in saline, Tigecycline lost its ability to kill TEX human leukemia cells (from IC50ca.5 uM when freshly prepared to IC50>50 uM after 4 days preincubation) as measured by CellTiter Flour assay[1]. In Vivo: Tigecycline (50 mg/kg; intraperitoneal injection; twice a day; for 11 days) reduces tumor volume and weight in NOD/SCID mice[1].
The peak plasma concentration (Cmax), the terminal half-life (t1/2), area under the plasma concentration-time curve (AUC), clearance (CL) and volume of distribution (Vz) are 22.8ug/mL, 108.9 min, 1912.2min*ug/mL, 26.1 mL/min/kg, 4109.4 mL/kg for Tigecycline in saline, respectively. The peak plasma concentration (Cmax), the terminal half-life (t1/2), area under the plasma concentration-time curve (AUC), clearance (CL) and volume of distribution (Vz) are15.7ug/mL, 110.3 min, 2036.5 min*ug/mL, 24.6 mL/min/kg, 3906.2 mL/kg for Tigecycline in formulation (60 mg/mL pyruvate, 3 mg/mL ascorbic acid, pH 7 in saline) , respectively[1].

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 500mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen